New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:10 EDTPFE, DDAIF, BMY, WAGOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: U.S. businesses took on new office space at a sluggish pace in Q4, as employers remained cautious about adding jobs, the Wall Street Journal reports...This week Walgreen Co. (WAG) executives will outline what's ahead for the drugstore chain in 2013, with some analysts saying a busy flu season and firmer prescription orders could help the company outperform its rivals, the Wall Street Journal reports...REUTERS: Major U.S. technology companies could miss estimates for Q4 earnings as "fiscal cliff" concerns likely led some corporate clients to tighten their belts last month and hold off on spending all of their 2012 IT budgets, Reuters reports...The U.S. dominates the list of places that global commercial real estate investors would prefer to invest their money this year, while China has lost some luster and Turkey has drawn more interest, according to an annual survey by the Association of Foreign Investors in Real Estate, Reuters reports...BLOOMBERG: China Investment Corp. may acquire a holding of 4% to 10% in Daimler AG (DDAIF), according to the Chinese newspaper People’s Daily which reported the country’s sovereign-wealth fund may buy a stake in the luxury car maker, Bloomberg reports...The return of $10B-plus drug deals may be here as pharmaceutical companies including Pfizer (PFE) and Bristol-Myers Squibb (BMY) may be ready to start buying again. Five of the largest U.S. drug makers had more than $70B in cash, near cash and short-term investments at the end of the Q3, Bloomberg reports.
News For WAG;DDAIF;PFE;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 27, 2015
05:28 EDTBMYAllied-Bristol Life Sciences announces licensing agreement with Yale University
Subscribe for More Information
August 26, 2015
17:28 EDTDDAIFBAIC chairman says in talks to buy major stake in Daimler AG, Bloomberg says
Subscribe for More Information
16:26 EDTDDAIFMajor automakers sued over allegedly 'deadly' keyless technology, Reuters says
A number of automakers have been named in a lawsuit alleging that keyless ignition technology can lead to "deadly" results due to carbon monoxide poisoning from cars left running under the belief that engines will automatically switch off, reports Reuters. Defendants include General Motors (GM), Ford (F), Fiat Chrysler (FCAU), Honda (HMC), Hyundai (HYMLF), Nissan (NSANY), Toyota (TM), Volkswagen (VLKAY), BMW (BAMXY), and Daimler's (DDAIF) Mercedes Benz, said Reuters. According to the plaintiffs, the carmakers had "actual knowledge" of the so-called risks and could have prevented 13 deaths and numerous injuries. Reference Link
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
August 25, 2015
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
09:45 EDTBMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Bank of America (BAC) upgraded to Outperform from Market Perform at Keefe Bruyette... Bristol-Myers (BMY) upgraded to Neutral from Underweight at Piper Jaffray... Chevron (CVX) upgraded to Neutral from Underperform at BofA/Merrill... Abercrombie & Fitch (ANF) upgraded to Overweight from Neutral... Nike (NKE) upgraded to Outperform from Market Perform at Telsey Advisory... DreamWorks (DWA) upgraded to Buy from Neutral at B. Riley... Caesarstone (CSTE) upgraded to Overweight from Equal Weight at Barclays... TransAlta (TAC) upgraded to Outperform from Market Perform at BMO Capital... Sarepta (SRPT) upgraded to Overweight from Neutral at Piper Jaffray... AutoZone (AZO) upgraded to Buy from Neutral at BofA/Merrill... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Jefferies... Allscripts (MDRX) upgraded to Buy from Hold at Argus... China Unicom (CHU) upgraded to Buy from Hold at Jefferies... Ross Stores (ROST) upgraded to Buy from Neutral at Buckingham.
08:16 EDTPFE, BMYBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
07:15 EDTDDAIFDaimler to cut 1,500 truckmaking jobs in Brazil, Bloomberg reports
Daimler is cutting 1,500 jobs at its Brazilian truckmaking unit amidst lack of recovery for demand for commercial vehicles in the country, Bloomberg reports. Reference Link
07:08 EDTBMYBristol-Myers upgraded to Neutral from Underweight at Piper Jaffray
Subscribe for More Information
August 23, 2015
12:35 EDTPFE, BMYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:11 EDTDDAIFDaimler AG could collaborate with Google, Apple, Reuters says
Subscribe for More Information
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
August 20, 2015
11:24 EDTPFEPfizer says Ibrance application validated by EMA
Subscribe for More Information
06:01 EDTBMYBristol-Myers announces Canadian approval of Daklinza
Subscribe for More Information
August 19, 2015
05:46 EDTBMYStocks with implied volatility movement; ESRX BMY
Subscribe for More Information
August 18, 2015
07:22 EDTBMYBristol-Myers combo data could push shares above $70, says JPMorgan
JPMorgan analyst Chris Schott says the risk/reward for shares of Bristol-Myers Squibb looks "very attractive" ahead of the World Conference on Lung Cancer, which begins September 6. Data at the conference supportive of an Opdivo/Yervoy combo would represent a clear catalyst for the shares, Schott tells investors in a research note. Bristol is "already extremely well-positioned" in the advanced non-small cell lung cancer market, and data suggesting that the company has addressed toxicity concerns with the combo could push the stock above $70, Schott argues. Bristol closed yesterday up 39c to $63.47. The analyst sees limited downside to stock even with disappointing results at the World Conference on Lung Cancer. He reiterates an Overweight rating on Bristol with a $75 price target.
August 17, 2015
08:43 EDTBMYBristol-Myers sells Ixempra to R-PHARM, terms not disclosed
R-PHARM announces the acquisition of Ixempra from Bristol-Myers Squibb. Ixempra received marketing approval from the FDA in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement. Financial terms were not disclosed.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use